CRNX — Crinetics Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $3.35bn
- $2.79bn
- $4.01m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 118 | 171 | 334 | 334 | 559 |
Net Total Receivables | 1.38 | 1.83 | 1.48 | 2.29 | 9.1 |
Prepaid Expenses | |||||
Total Current Assets | 123 | 177 | 345 | 345 | 574 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6.46 | 5.41 | 4.72 | 4.99 | 57.4 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 130 | 183 | 351 | 352 | 635 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.34 | 10.5 | 16 | 27.7 | 43.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 13.2 | 14.5 | 19.1 | 35.8 | 96.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 117 | 169 | 332 | 316 | 539 |
Total Liabilities & Shareholders' Equity | 130 | 183 | 351 | 352 | 635 |
Total Common Shares Outstanding |